Business Context and Reporting Period
This Form 8-K is filed by Blackboxstocks Inc. (trading symbol: BLBX) on January 7, 2025. The registrant is incorporated in Nevada and lists its common stock on the NASDAQ Capital Market. The report addresses specific compliance failures regarding Nasdaq listing rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes and Compliance Issues
- Failure to Hold Annual Meeting (Rule 5620): The Company failed to hold its 2024 Annual Meeting of Stockholders by the required deadline of December 31, 2024. The meeting is now scheduled for February 7, 2025.
- Board Composition and Audit Committee (Rule 5605): Following the unexpected passing of Director Ray Balestri on January 4, 2025, the Company is no longer in compliance with Nasdaq corporate governance requirements:
- Board Independence: The board now consists of four members, only two of whom are Independent Directors. This fails the requirement for a majority of independent directors.
- Audit Committee Size: The Audit Committee is reduced to two members, failing the requirement for a minimum of three independent members.
Outlook, Management Commentary, and Risks
Management states the Company is currently reviewing and evaluating potential options to regain compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) within the cure period provided by Nasdaq. The primary risk identified is the potential delisting or failure to satisfy continued listing standards if compliance is not restored.
Investor Verification Checklist
- Confirm the date and agenda of the rescheduled 2024 Annual Meeting (February 7, 2025).
- Monitor announcements regarding the appointment of new directors to restore the majority of independent directors on the board.
- Verify the appointment of a third independent member to the Audit Committee.
- Check for subsequent filings regarding the Company's status with Nasdaq during the cure period.